title: Effect of a single oral dose of two erythromycin ethylsuccinate formulations on gastric emptying in healthy volunteers: a scintigraphic study.
abstract: Macrolides are potential gastrokinetic agents. The purpose of this study was to assess the effect of a single oral dose of two erythromycin formulations on gastric emptying of the solid and liquid phases in twelve healthy volunteers and to seek a correlation between pharmacokinetic parameters and changes in gastric emptying. The gastric emptying times of liquids and solids were measured simultaneously by means of a scintigraphic technique after a single oral administration of amorphous erythromycin ethylsuccinate (500 mg), crystalline erythromycin ethylsuccinate (1000 mg) or a placebo, in a double-blind crossover study in three separate weeks. Blood samples were obtained for erythromycin assay. The two oral formulations induced a similar acceleration of gastric emptying. When compared to the placebo, both erythromycin preparations significantly shortened the gastric transit time of solids and liquids (respectively 30% and 20% on average, p < 0.01). The incidence of gastrointestinal side-effects was similar with the two erythromycin forms and the placebo. No correlation was found between the peak serum erythromycin concentrations and the solid or liquid gastric half-lives. With the amorphous formulation, the area under the plasma time-concentration curves was small and solid and liquid gastric emptying were strongly accelerated, pointing to a direct effect on the gastrointestinal smooth muscle.
authors.affiliation: Département de Pharmacologie Clinique, INSERM U13, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Delatour
authors.forename: D
authors.initials: D
authors.lastname: Le Guludec
authors.forename: F
authors.initials: F
authors.lastname: Caron
authors.forename: F
authors.initials: F
authors.lastname: Faurisson
authors.forename: J C
authors.initials: JC
authors.lastname: Torlotin
authors.forename: B
authors.initials: B
authors.lastname: Rouveix
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D015643:Erythromycin Ethylsuccinate / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D005746:Gastric Emptying / Q000187:drug effects*; D006801:Humans; D008297:Male; D011877:Radionuclide Imaging / Q000379:methods*
chemical_list: D000900:Anti-Bacterial Agents; D015643:Erythromycin Ethylsuccinate